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Soňa Muzikárová (GLOBSEC) says countries with a reputation for innovation and strong institutions
are vaccinating their populations faster.
Israel leads the world in COVID vaccinations, with over half the adult population fully jabbed. It also
happens to be a highly innovative country. The fact that some of the top performers in vaccination
performers also occupy top spots in global innovation rankings is hard to ignore. Israel has been
dubbed a “start-up nation”, a reputation that precedes it in academia, business, and foreign
relations. The UK and US also have a longstanding tradition of innovation, consistently ranking in
top positions by various measures of performance.
Figure 1: Vaccination rate by country (countries with a population > 1 million and that use
internationally peer-reviewed vaccines)
Source: OWGD, 2021
Within continental Europe, the Nordic countries – Denmark, Norway, and Finland – measure up to
much larger and geopolitically more signi cant economies in terms of innovation, capitalising on
their high-quality education systems and tradition in invention. The Estonian approach to
digitalisation is recognised and imitated worldwide. In Central and Eastern Europe, Slovenia and
Austria surpass their regional peers as local innovation hubs.
Figure 2: National log vaccination rate v GII innovation score
 
Source: Global Innovation Index (GII) Rankings 2020, OWGD, 2021. Note: GII innovation scores,
developed by Cornell University, INSEAD, and the World Intellectual Property Organization (WIPO),
serve as a yardstick for measuring innovation by the UN General Assembly, and include relevant
innovation inputs (human capital, research, business & market sophistication) and outputs
(knowledge, tech, and creative results).
Analysis of a sample of over 90 countries with populations over 1 million shows a positive
correlation between the ability to innovate and the COVID vaccination rate. To some extent, the
robustness of domestic research – especially, domestic vaccine development – may help in
boosting country vaccination rates. The unparalleled speed of COVID vaccine development was
predicated on a series of innovations and investments preceding the pandemic. For example, both,
P zer-BioNTech and Moderna vaccines piggyback on the pre-COVID era synthetic messenger RNA
technology – a clever variation of the natural substance that directs protein production in cells
throughout the body – which was researched as early as in the 1990s. These vaccines were
developed in the US and the UK, the 2nd and 3rd vaccination top performers, while Germany, where
BioNTech is headquartered, has the  fth highest net vaccination rate in the world. But robustness of
domestic R&D alone is not enough to explain Israel’s success. Israeli companies neither developed
nor produced the vaccines that millions of its citizens are receiving, and yet it has successfully
secured and distributed them to over half of its population in a few months.
A vaccination centre in the Wirral, UK. Photo:Tim Jokl via a CC-BY-NC 2.0 licence
The e cacy of national vaccination campaigns may also depend on less glossy  elds such as
manufacturing, logistics, procurement channels and practices. The agility and institutional
fundamentals of the public sector are important, too, including a country’s ability to leverage
existing trade links, policy foresight, and government digitalisation. A plot against the latest World
Bank Governance Indicators appears to corroborate this theory. Institutional quality seems to
explain roughly 30 per cent of variation in country vaccination rates.
Figure 3: Institutional quality is positively correlated with vaccination rates
Source: World Bank Governance Indicators database, 2021.
While Israel outbid its European peers on the P zer vaccines and agreed to retain product liability,
its main asset in the vaccination race has been its highly centralised and digitalised healthcare
system. Prior to the pandemic, Israel had budgeted almost $300 million to consolidate and
standardise its healthcare databases, making it a prime location for large-scale medical studies
requiring big data. Other vaccination frontrunners, particularly the UK, Denmark and Norway, are
also notable digital government leaders.
Still, a reputation for innovation and effective governments fail to explain the lacklustre vaccination
performance of some other countries, including South Korea, Japan, Thailand and New Zealand.
They have done well in tackling the virus by broad testing, tracking and tracing, leveraging their
experience with past epidemics and exploiting novel technologies. Although some of them are
facing resurgences of the virus, they put mechanisms in place to control the pandemic early on and
do not feel the same urgency to ramp up vaccinations. Europe, the US and other major blocs face a
very different foe: rampant, uncontrolled spread of the virus, which threatens their healthcare
systems, economies and social stability.
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